Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.2800 (-5.88%) ($5.2800 - $5.2800) on Tue. Apr. 6, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.44% (three month average) | RSI | 50 | Latest Price | $5.2800(-5.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP advances 1.3% a day on average for past five trading days. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) ACES(69%) TAN(33%) UNG(38%) XLU(14%) XBI(26%) | Factors Impacting ADAP price | ADAP will decline at least -2.22% in a week (0% probabilities). IWD(-76%) IDRV(-6%) IYT(-31%) JETS(-21%) IWN(-16%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.22% (StdDev 4.44%) | Hourly BBV | -2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.32 | 5 Day Moving Average | $5.36(-1.49%) | 10 Day Moving Average | $5.26(0.38%) | 20 Day Moving Average | $5.32(-0.75%) | To recent high | -22.8% | To recent low | 5.1% | Market Cap | $816m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |